GHRP-6
Also known as: Growth Hormone Releasing Peptide-6
GHRP-6 is a synthetic growth hormone releasing peptide and ghrelin-mimetic studied in early research for its reported ability to stimulate growth hormone release and appetite. It is not approved for human use in Australia.
- Category
- Growth Hormone Secretagogue
- Reported half-life
- Reported ~15-60 minutes (varies by study)
- Common forms
- Lyophilised powder for reconstitution, Injectable solution
- Research status
- Not approved for human use in Australia; investigated in early clinical and preclinical research only. No marketed human therapeutic product.
- Last updated
- 21 June 2026
Claimed effects
The following effects are reported or claimed by users and in early research. They are not established medical facts and many are not supported by large human trials.
- Reported to stimulate a pulse of growth hormone release
- Reported to strongly stimulate appetite via ghrelin-receptor activity
- Users report interest in recovery and body composition
- Early research indicates possible cytoprotective effects in animal models
How it is reported to work
GHRP-6 is reported to mimic ghrelin and bind the growth hormone secretagogue receptor, prompting the pituitary to release a pulse of growth hormone. It is also widely reported to produce a pronounced increase in appetite through the same receptor system. These mechanisms are described in early and animal research and are not established for general human use.
Background
GHRP-6 is one of the earliest growth hormone releasing peptides - a ghrelin-mimetic reported to prompt growth hormone release while also producing a notably strong appetite-stimulating effect. It is frequently discussed alongside GHRP-2 and hexarelin in online communities. This page is educational information, not medical advice.
What the research actually shows
GHRP-6 has been studied mainly in early-stage and animal research, where it is reported to trigger growth hormone release and, in some models, cytoprotective effects. Large, long-term human clinical trials confirming benefits and safety are not available.
| Evidence type | Status |
|---|---|
| Early/animal research | Present |
| Large human trials | Lacking |
| Australian approval | None |
What people use it for (reported)
Online, people report using GHRP-6 in attempts to support recovery and body composition, and note its strong reported appetite effect. These are anecdotal reports, not validated clinical results. Studies suggest the mechanism involves the growth hormone secretagogue receptor.
Things to be aware of
GHRP-6 is not approved for human use in Australia. Strong appetite and growth hormone pathway effects can have unintended consequences, and grey-market product purity cannot be verified by sight.
If you have a health concern, the appropriate step is to talk to a qualified healthcare professional rather than self-experimenting. This article is not an endorsement and does not recommend obtaining or using GHRP-6.
Reported positives & side effects
Compiled from research and community reports. These are reported outcomes, not guarantees or medical advice, individual experiences vary widely.
Reported positives
- Reported to stimulate a pulse of growth-hormone release
- Reported to strongly increase appetite, of interest to those struggling to eat enough
- Users report improved recovery and sleep
- Reported possible cytoprotective effects in animal models
- Reported possible rises in IGF-1 over time
Common side effects
- Strong increase in appetite and hunger
- Injection-site reactions such as redness or itching
- Facial flushing or head-rush after injection
- Water retention or puffiness
- Tingling or numbness in the hands
Rare / serious side effects
- Raised prolactin or cortisol reported at higher doses in some studies
- Changes in blood-sugar control
- Allergic-type reactions
- Reactions attributed to impurities in unregulated grey-market product
Reported misuse & overdose risks
What has been reported to happen with overuse, excessive dosing, or long-term misuse of GHRP-6. Listed so you can make an informed decision, not to suggest any use is safe.
- Its very strong appetite stimulation is reported to drive excessive overeating and unwanted weight gain when overused
- Higher doses are reported to raise prolactin and cortisol, a frequently cited reason against overuse
- Chronic high-dose use is reported to risk down-regulating the body's own growth-hormone pulses, suppressing natural production
- Sustained growth-hormone and IGF-1 elevation from overuse is reported to risk insulin resistance, fluid retention and theoretical concern about abnormal tissue growth
- Unverified grey-market product is reported to risk contamination and incorrect dosing
Reported results timeline
Roughly how long people report it takes to notice effects. A general guide from reports, not a promise, and not advice. The appetite-stimulating effect is often reported within hours of the first dose, while body-composition changes are reported to build over several months.
First effects
Appetite surge within hours to days
Noticeable change
Recovery and well-being ~4 weeks
Clear results
Body-composition changes ~12 weeks
Peak effect
Fuller effects reported ~16-20 weeks
Commonly reported dosing & protocol
Reported figures only, NOT a recommendation or dosing advice. These are numbers people report using, compiled for education so you can make an informed decision. We do not advise anyone to take GHRP-6. Many peptides are not approved for human use in Australia. Speak to a qualified healthcare professional.
| Route | Subcutaneous injection |
|---|---|
| Typical reported dose | Reported community figures of roughly 100–300 mcg per dose (often paired with a GHRH analogue) |
| Frequency | Reported as 1–3× daily |
| Cycle length | Reported cycles of about 8–12 weeks, then a break |
Reported reconstitution (mg → units)
Worked example only: a 5 mg vial + 2 mL bacteriostatic water = 2.5 mg/mL. A 100 mcg (0.1 mg) dose ≈ 0.04 mL = 4 units on a U-100 insulin syringe; a 300 mcg (0.3 mg) dose ≈ 0.12 mL = 12 units.
Work out the units for your vial → CalculatorCommonly reported community patterns describe one or more daily injections, often paired with a GHRH analogue, run in cycles of roughly 8 to 12 weeks with a break. Some report timing it to help reach calorie goals during a bulk. These are reported patterns only, not a recommendation, and GHRP-6 is not approved for human use in Australia.
Best used with / commonly stacked with
Combinations people report using together. Reported, not recommended, stacking can increase risks.
Classic reported pairing of a ghrelin-mimetic with a GHRH analogue to amplify the growth-hormone pulse
Reported as an alternative GHRH-analogue partner
Reported as a more selective ghrelin-mimetic users rotate to when they want less appetite and prolactin effect
Safety notes
GHRP-6 is not approved by the TGA for human use in Australia, and long-term human safety data is lacking. Strong appetite and growth hormone effects can carry risks, and grey-market product purity cannot be verified by consumers. Anyone considering it should first consult a qualified healthcare professional.